Table 1.
Characteristics of the two randomly divided cohorts of kidney recipients.
| Discovery cohort (n = 286) | Validation cohort (n = 153) | p value | |
|---|---|---|---|
| Recipient age, years, mean ± SD | 52.2 ± 13.5 | 51.8 ± 13.0 | 0.78 |
| Male recipient, N (%) | 191 (66.8%) | 100 (65.4%) | 0.76 |
| Time on dialysis, months | 17.8 (7.1–31.2) | 16.8 (6.1–26.9) | 0.58 |
| Cause of chronic renal failure, N (%) | 0.08 | ||
| Glomerulonephritis | 86 (30.1%) | 53 (34.6%) | |
| Chronic tubulointerstitial nephropathy | 31 (10.8%) | 23 (15.0%) | |
| Nephroangiosclerosis | 22 (7.7%) | 11 (7.2%) | |
| Polycystic kidney disease | 45 (15.3%) | 21 (13.7%) | |
| Diabetic nephropathy | 42 (14.7%) | 8 (5.2%) | |
| Unknown cause | 48 (16.8%) | 32 (20.9%) | |
| Others | 12 (4.2%) | 5 (3.3%) | |
| Donor age, years, mean ± SD | 43.0 ± 14.3 | 42.6 ± 14.1 | 0.73 |
| Male donor, N (%) | 209 (73.6%) | 112 (74.2%) | 0.90 |
| Donor type, N (%) | 0.65 | ||
| Brain death | 111 (38.8%) | 56 (36.6%) | |
| Circulatory death | 175 (61.2%) | 97 (61.2%) | |
| Immunosuppressive treatment, N (%) | 0.87 | ||
| Thymoglobulin + FK + MMF + P | 98 (34.3%) | 54 (35.3%) | |
| IL2R + FK + MMF + P | 127 (44.4%) | 69 (45.1%) | |
| FK + MMF + P | 54 (18.9%) | 28 (18.3%) | |
| CsA + MMF + P | 2 (0.7%) | 0 (0) | |
| FK + SRL + P | 1 (0.3%) | 1 (0.7%) | |
| Belatacept + MMF + P | 4 (1.4%) | 1 (0.7%) | |
| Follow-up time, months (median [IQR]) | 74.9 (53.8–99.5) | 73.0 (50.2–97.5) | 0.54 |
| Delayed graft function, N (%) | 143 (50.0%) | 80 (52.3%) | 0.65 |
| HLA-A mismatch, N (%) | 0.56 | ||
| 0 | 24 (8.4%) | 17 (11.3%) | |
| 1 | 118 (41.4%) | 64 (42.4%) | |
| 2 | 143 (50.2%) | 70 (46.4 %) | |
| HLA-B mismatch, N (%) | 0.55 | ||
| 0 | 12 (4.2%) | 4 (2.6%) | |
| 1 | 112 (39.3%) | 66 (43.4%) | |
| 2 | 161 (56.5%) | 82 (53.9%) | |
| HLA-DR mismatch, N (%) | 0.13 | ||
| 0 | 34 (11.9%) | 18 (11.8%) | |
| 1 | 123 (43.2%) | 80 (52.6%) | |
| 2 | 128 (44.9%) | 54 (35.5%) | |
| Acute total rejection, N (%) | 80 (28.0%) | 39 (25.5%) | 0.58 |
| Acute rejection Banff ≥ 2, N (%) | 55 (19.2%) | 28 (18.3%) | 0.81 |
| Acute humoral rejection, N (%) | 20 (7.0%) | 10 (6.5%) | 0.86 |
| Genotype frequency GA/AA TNF-α −308, N (%) | 49 (17.1%) | 26 (17.0%) | 0.97 |
| Graft loss, N (%) | 49 (17.1%) | 21 (13.7%) | 0.35 |
FK: tacrolimus; MMF: mycophenolate; P: prednisone; IL2R: interleukin- (IL-) 2 receptor antagonist; CsA: cyclosporin A; SRL: sirolimus.